Takayasu Arteritis

• Human Leukocyte Antigen (HLA) Association and Genetic Susceptibility: TA shows strong association with HLA-B52 (particularly in Asian populations) and **HLA-DRB1*0404** (in Latin American and other populations), suggesting adaptive immune recognition of antigens on vascular endothelium. Genome-wide association studies have identified additional loci including variants in IL6R, FCGR2A, and RPS9, indicating both innate and adaptive immunity involvement. The genetic predisposition combined with unknown environmental triggers (possibly molecular mimicry from infections) initiates disease pathogenesis.

• Th1/Th17-Mediated Chronic Inflammation: The initial phase involves CD4+ T cell infiltration of the media and adventitia of large arteries, particularly at the aortic arch and descending aorta. T cells produce interferon-gamma (IFN-γ), interleukin-17 (IL-17), and tumor necrosis factor-alpha (TNF-α), creating a predominantly Th1/Th17 cytokine milieu. This contrasts with giant cell arteritis (GCA), which shows Th1/Th2 balance. IL-6 appears particularly important in TA pathogenesis, as evidenced by the genetic association and the therapeutic response to IL-6 receptor antagonists like tocilizumab. B cell infiltration and autoantibody formation (anti-aortic antibodies, anti-endothelial cell antibodies) contribute to sustained inflammation.

• Arterial Wall Structural Changes and Progressive Fibrosis: The chronic inflammatory infiltrate triggers smooth muscle cell activation and proliferation within the medial layer. Activated macrophages and fibroblasts produce excessive transforming growth factor-beta (TGF-β) and other pro-fibrotic cytokines, leading to progressive intimal hyperplasia, medial hypertrophy, and ultimately adventitial fibrosis. This fibroinflammatory process narrows the arterial lumen, causing progressive stenotic lesions. Concurrent destruction of the medial elastic lamina reduces arterial compliance and can lead to paradoxical aneurysmal dilatation in some arterial segments. The result is segmental and asymmetric involvement, often with skip lesions characteristic of large-vessel vasculitis.

• Endothelial Dysfunction and Prothrombotic State: Chronic inflammation damages the endothelial layer, exposing subendothelial tissue factor and promoting a prothrombotic microenvironment. Arterial wall inflammation increases production of tissue factor, phosphatidylserine, and other procoagulant substances. Stenotic lesions create turbulent flow and local hypoxia, further increasing thrombosis risk. This explains the significant incidence of arterial thrombosis in TA patients, particularly affecting coronary and cerebral circulation.

• Aortic Regurgitation Development: Progressive dilation of the aortic root and valve annulus occurs secondary to both inflammation and loss of elastic fiber integrity in the aortic wall. The inflammatory process directly extends to the aortic valve cusps in some cases, causing valve incompetence. Chronic volume overload from severe aortic regurgitation leads to left ventricular hypertrophy and eventual systolic dysfunction.

• Female Gender and Reproductive Age: Approximately 80–90% of TA cases occur in women, with peak incidence between ages 15–35 years. Estrogen's role remains incompletely understood but may relate to effects on innate immunity, regulatory T cells, and endothelial function. The female predominance is more pronounced in TA than in other large-vessel vasculitis (GCA shows slight female predominance; polyarteritis nodosa is more common in males).

• Asian, Indian, and Latin American Ancestry: Geographic clustering is striking, with TA endemic in East Asia (Japan, Korea, China), the Indian subcontinent, and Latin America (Mexico, Brazil). The prevalence in Japan is approximately 10–16 cases per million population, whereas North American prevalence is estimated at 0.2–0.5 cases per million. This distribution correlates with HLA allele frequencies, suggesting genetic predisposition specific to these populations.

• HLA Associations and Genetic Polymorphisms: HLA-B52 confers the strongest risk in Asian populations (with odds ratios 20–45 in some studies). **HLA-DRB1*0404 and HLA-DRB1*0401** are associated with disease in Latin American and Caucasian populations, respectively. Polymorphisms in IL-6R, involving single nucleotide variants that increase IL-6 signaling, predispose to more aggressive disease. FCGR2A polymorphisms affecting Fc-gamma receptor function modify immune complex clearance and complement activation.

• Chronic Infections as Environmental Triggers: Molecular mimicry from chronic bacterial infections (particularly Mycobacterium tuberculosis, Streptococcus pyogenes, Treponema pallidum) has been hypothesized as potential triggers, although causative organisms have not been definitively identified. The frequency of tuberculosis in TA-endemic regions raises the possibility of cross-reactive T cell responses, though TA is not considered primarily infectious in origin.

• Other Predisposing Conditions: TA occasionally coexists with or follows other autoimmune conditions including inflammatory bowel disease (IBD), particularly in Asian cohorts, and systemic lupus erythematosus. Some cases show association with previous live attenuated vaccination, though causality remains uncertain.

• Early/Inflammatory Phase (Systemic Symptoms):
• Constitutional symptoms: Fever (low-grade, often evening), night sweats, fatigue, and malaise typically precede vascular manifestations by weeks to months. These nonspecific symptoms often lead to initial diagnostic confusion and delays in recognition.
• Arthralgias and arthritis: 50–60% of patients develop articular involvement, usually affecting large joints (knees, ankles, wrists) with symmetric polyarthritis pattern. Joint symptoms may mimic rheumatoid arthritis, though the arthritis typically resolves without permanent deformity.
• Myalgias: Diffuse myalgias occur in approximately 25% of patients during the inflammatory phase.

• Late/Occlusive Phase (Vascular Insufficiency):
• "Pulseless disease" and absent/diminished pulses: The classic finding reflects progressive stenosis of brachiocephalic, left common carotid, and/or left subclavian arteries. Patients may have asymmetric blood pressure readings between arms (difference >10 mmHg, often >20 mmHg) or between upper and lower extremities. Complete absence of pulses in one or both upper extremities represents the pathognomonic presentation. Diminished or absent carotid pulses may be appreciated on palpation.

• Claudication symptoms: Upper extremity claudication occurs when subclavian/axillary stenosis impairs blood flow, causing arm pain and fatigue with use. Lower extremity claudication similarly reflects aortic bifurcation or iliac disease (present in 40% of TA cases). Patients describe characteristic cramping pain in affected limbs with exertion that resolves with rest.

• Hypertension and Renovascular Features: Hypertension occurs in 40–70% of patients through two mechanisms: (1) renal artery stenosis from direct involvement of ostial renal arteries (present in ~55% of angiography cases) causing activation of the renin-angiotensin system, and (2) aortic stiffness from inflammation and fibrosis reducing vascular compliance. Renovascular hypertension may be resistant to medical therapy. Flash pulmonary edema or acute hypertensive encephalopathy can occur with severely narrowed renal arteries.

• Cerebrovascular Ischemia: Carotid artery stenosis predisposes to cerebral ischemic events. Patients experience transient ischemic attacks (TIAs), amaurosis fugax, or frank stroke. The distribution is often atypical compared to atherosclerotic stroke (more anterior circulation, younger age). Vertebral artery involvement is less common than carotid disease. Posterior circulation strokes occur when subclavian involvement compromises vertebral flow (subclavian steal phenomenon).

• Aortic Insufficiency and Congestive Heart Failure: Progressive aortic regurgitation develops in 10–40% of patients as the aortic root dilates. Patients develop a diastolic decrescendo murmur best heard at the left sternal border with patient leaning forward. Chronic aortic regurgitation leads to left ventricular hypertrophy and eventual dilated cardiomyopathy with systolic dysfunction. Presentation includes exertional dyspnea, orthopnea, and peripheral edema. Acute severe aortic regurgitation from rupture or aneurysm dissection presents as acute pulmonary edema and cardiogenic shock.

• Coronary Artery Involvement: TA affects coronary ostia and proximal coronary arteries in 10–15% of angiography cases. Coronary involvement causes exertional angina or myocardial infarction in young women without traditional atherosclerotic risk factors. Sudden cardiac death can occur from severe coronary stenosis or ostial coronary involvement.

• Pulmonary Artery Involvement: Found in 40–45% of angiography cases, pulmonary artery narrowing is often clinically silent but may cause dyspnea, pulmonary hypertension, and right ventricular dysfunction. Pulmonary hypertension develops from multiple pulmonary artery stenoses or chronic hypoxia and substantially worsens prognosis.

• Physical Examination Findings:
• Blood pressure differential: Measurement of blood pressure in both arms; difference >10 mmHg is suggestive and >20 mmHg is highly specific for large-vessel vasculitis. Measurement in lower extremities reveals gradient (systolic BP typically 10–40 mmHg higher in legs than arms).
• Diminished or absent pulses: Systematic palpation of carotid, brachial, radial, femoral, dorsalis pedis, and posterior tibial pulses; absence of pulses in upper extremities is classic but can be subtle early in disease.
• Aortic regurgitation murmur: High-pitched diastolic decrescendo murmur at left sternal border, may be accompanied by systolic flow murmur from increased stroke volume. Associated findings include wide pulse pressure, bounding water-hammer pulses (Corrigan pulses), and Quincke's sign (nail bed pulsations).
• Bruits: Carotid, subclavian, or abdominal bruits reflect turbulent flow through stenotic vessels.
• Retinopathy: Characteristic "ocular ischemic syndrome" includes dilated conjunctival and episcleral vessels, microaneurysms, cotton-wool spots, and optic disc neovascularization from chronic cerebral and ocular hypoperfusion.
• Skin manifestations: Erythema nodosum occurs in a subset of patients, particularly in those with concurrent IBD. Pyoderma gangrenosum is rarely associated.

• Clinical Variants and Atypical Presentations:
• Isolated aortic regurgitation: Some patients present with gradually progressive aortic insufficiency and left ventricular hypertrophy without prominent systemic symptoms or obvious vascular stenosis, making diagnosis challenging.
• Cardiac or pulmonary presentation: Acute myocarditis with elevated troponins and dilated cardiomyopathy or isolated pulmonary hypertension with dyspnea may be initial presenting features.
• Fulminant course: Rare presentations include acute aortic dissection, aortic rupture, or acute large-vessel occlusion.
• Silent progression: Some patients have angiographically evident significant disease without constitutional symptoms, representing quiescent or burned-out disease.

• Clinical History and Presentation:
• Age of onset <50 years (typically 15–35) in a female from Asia, India, or Latin America with constitutional symptoms strongly suggests TA.
• Progressive claudication symptoms, asymmetric pulses, or hypertension in a young woman warrants investigation.
• New aortic regurgitation in a young patient without endocarditis history or systemic lupus erythematosus should prompt TA consideration.

• Laboratory Testing:
• Acute Phase Reactants: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are elevated during active inflammation but are nonspecific. ESR typically ranges 40–100 mm/hour or higher during active disease. However, 10–20% of patients may have normal ESR/CRP despite active disease, and markers normalize with treatment even if vascular lesions progress (dissociation between inflammatory and vascular activity is characteristic). CRP may be slightly more sensitive for active disease than ESR.
• Complete Blood Count: Mild anemia and leukocytosis (WBC 10,000–15,000) occur during inflammatory phase. Normocytic anemia from chronic inflammation is common.
• Comprehensive Metabolic Panel: Serum creatinine elevation suggests renal artery stenosis or concurrent glomerulonephritis. Hypoalbuminemia reflects chronic inflammation.
• Autoantibodies and Serologies: Antinuclear antibodies (ANA) are positive in 10–20% of TA patients but are not diagnostic. Rheumatoid factor may be positive (15–20% of cases). Anti-neutrophil cytoplasmic antibody (ANCA) is typically negative (helps exclude ANCA-associated vasculitis). Anticardiolipin and anti-beta-2 glycoprotein I antibodies are variably present but not diagnostic.
• Other Laboratories: Liver function tests are usually normal unless concurrent IBD. Lipid panel may show elevated cholesterol from nephrotic syndrome if glomerulonephritis is present.

• Imaging Studies (definitive diagnosis):
• Contrast-Enhanced CT Angiography (CTA) of Chest, Abdomen, and Pelvis: CTA is the first-line imaging modality for diagnostic confirmation. Characteristic findings include:
• Smooth, symmetric narrowing of aortic lumen (tapered appearance)
• Concentric thickening of the aortic wall (wall thickness >3 mm) reflecting inflammatory infiltration
• Aortic branch stenosis (ostial narrowing of brachiocephalic, carotid, subclavian, renal arteries most common)
• Skip lesions with both stenotic and aneurysmal segments
• Aortic root dilatation and aortic regurgitation assessment
• Pulmonary artery involvement (narrowing or dilatation)

• Magnetic Resonance Angiography (MRA): Excellent spatial resolution without radiation; particularly useful for follow-up imaging. Wall edema (increased T2 signal in vessel wall) indicates active inflammation. Contrast-enhanced MRA shows vessel anatomy similar to CTA. Late gadolinium enhancement may indicate active inflammation but is less standardized than in cardiac imaging.

• Positron Emission Tomography (PET) with 18F-FDG: Shows increased metabol

Immediate stabilisation (before immunosuppression)

• Vascular emergencies first: acute stroke, myocardial infarction from ostial coronary disease, aortic dissection/rupture, or hypertensive emergency from renal artery stenosis take precedence over vasculitis-specific therapy.
• Measure blood pressure in the unobstructed limb: with subclavian stenosis, cuff pressure underestimates central pressure, and treating to the falsely low reading can precipitate cerebral or renal hypoperfusion.

First-line therapy (ACR/Vasculitis Foundation 2021 guideline for GCA and Takayasu arteritis)

• Systemic glucocorticoids: high-dose oral prednisone is the induction backbone; IV pulse methylprednisolone is reserved for organ- or vision-threatening ischemia. Steroids suppress the Th1/Th17 cytokine drive but do not reverse established fibrotic stenosis.
• Concurrent non-glucocorticoid immunosuppressive at diagnosis: ACR/VF recommends starting a steroid-sparing agent with the steroid rather than waiting for relapse — antimetabolites (methotrexate, azathioprine, mycophenolate) are typical, since glucocorticoid monotherapy relapses in most patients during taper.

Escalation and biologics

• TNF-alpha inhibitors (infliximab) or IL-6 receptor antagonists (tocilizumab) for refractory or relapsing disease; ACR/VF conditionally favors a TNF inhibitor over tocilizumab in Takayasu. Screen for latent tuberculosis and hepatitis B before either — relevant given the TB-endemic geography of this disease.
• Adjuncts: bone-protective therapy and infection prophylaxis per the steroid burden.

Revascularisation

• Defer to quiescent disease whenever possible; operating on an inflamed vessel invites anastomotic aneurysm and restenosis. ACR/VF recommends surgical bypass grafting over endovascular angioplasty/stenting for critical arterial stenosis, and repair of aortic root/ascending aneurysm or severe aortic regurgitation follows ACC/AHA valvular disease principles.

What to avoid

• Routine antiplatelet therapy is not recommended absent ischemic or other indication (ACR/VF).
• Methotrexate and mycophenolate in pregnancy: both are teratogenic/abortifacient and contraindicated in pregnancy — mandatory in a population that is overwhelmingly women of reproductive age. Counsel on reliable contraception and allow washout before conception; azathioprine (with glucocorticoids) is the antimetabolite of choice when pregnancy is planned or discovered. See the obstetric point under complications.
• ACE inhibitors/ARBs are hazardous in bilateral or solitary-kidney renal artery stenosis, and all are contraindicated in pregnancy.
• Long-term glucocorticoid monotherapy and revascularisation during active inflammation.

Disease-related — vascular

• Aortic dissection or aneurysm rupture (emergency): destruction of the medial elastic lamina by inflammation weakens the wall; signals are tearing chest/back pain, new pulse or BP asymmetry, widened mediastinum, or hemodynamic collapse.
• Stroke and TIA (emergency): carotid or vertebral stenosis plus a prothrombotic endothelial surface; amaurosis fugax, focal deficit, or syncope in a young woman.
• Myocardial infarction (emergency): ostial/proximal coronary inflammation causes ischemia without atherosclerotic risk factors — troponin elevation and ischemic ECG changes in a patient under 40.
• Renovascular hypertension: ostial renal artery stenosis activates the renin–angiotensin system; signalled by treatment-resistant hypertension, abdominal bruit, or flash pulmonary edema. Malignant hypertension with encephalopathy is an emergency.
• Aortic regurgitation with heart failure: root dilatation widens the annulus; a decrescendo diastolic murmur with wide pulse pressure and progressive exertional dyspnea. Acute severe AR from dissection is an emergency.
• Pulmonary hypertension and right heart failure: multifocal pulmonary artery stenosis; loud P2, exertional dyspnea, RV strain on echo.
• Critical limb or mesenteric ischemia: postprandial abdominal pain, rest pain, or tissue loss.

Treatment-related

• Glucocorticoid toxicity: osteoporosis and fragility fracture, avascular necrosis, hyperglycemia, cataract/glaucoma, adrenal suppression, and infection — the reason ACR/VF pairs steroids with a steroid-sparing agent from the outset.
• Biologic-associated infection: TNF inhibitors reactivate latent tuberculosis (screen first) and predispose to granulomatous infection; new fever or cough demands workup, not a steroid increase.
• Tocilizumab pitfall: IL-6 blockade normalises CRP and ESR even with progressing arterial disease, so serial imaging — not acute-phase reactants — must guide monitoring. Watch for GI perforation, especially with diverticular disease.
• Post-procedural restenosis and graft failure: high after angioplasty/stenting, particularly if performed during active inflammation; recurrent claudication or a new bruit signals it.

• Pulseless disease in a young woman of Asian, Indian, or Latin American ancestry is the stem's signature: constitutional symptoms plus diminished radial pulses, arm-to-arm systolic BP difference, and a subclavian or carotid bruit.
• Single best next step after the exam findings: non-invasive large-vessel imaging of the aorta and its branches — CT angiography or MR angiography — not a temporal artery biopsy and not carotid duplex alone. Biopsy has no role in routine Takayasu diagnosis because the disease is patchy and the vessels are inaccessible.
• The association examiners test: HLA-B52, particularly in Japanese cohorts. Pair it with ANCA-negative serology, which is the discriminator from granulomatosis with polyangiitis.
• Takayasu versus giant cell arteritis: same granulomatous large-vessel histology, but Takayasu presents with aortic arch branch stenosis in the young, while GCA is a disease of headache, jaw claudication, and vision loss after age 50. Age is the cleanest separator on a stem.
• Know the instruments precisely: the 1990 ACR classification criteria for Takayasu require age at disease onset ≤40 years, whereas the 2022 ACR/EULAR classification criteria use an entry requirement of age ≤60 at diagnosis plus imaging evidence of large-vessel vasculitis. "Under 50" is a teaching heuristic, not a criterion — for exams, think onset before 40, and remember GCA is essentially never diagnosed before 50.
• Classic distractors to reject:
• Coarctation of the aorta: also gives upper–lower extremity BP gradient in a young patient, but there are no inflammatory markers, no constitutional symptoms, and rib notching on chest radiograph.
• Fibromuscular dysplasia: renovascular hypertension in a young woman, but string-of-beads mid-to-distal renal artery on angiography with normal ESR/CRP; Takayasu hits the ostium.
• Treatment pearl: high-dose glucocorticoids induce remission, but ACR/Vasculitis Foundation guidance adds a steroid-sparing immunosuppressive at the start; refractory disease escalates to a TNF inhibitor or tocilizumab. In a patient who may conceive, azathioprine — not methotrexate or mycophenolate.
• Monitoring pearl: normal ESR/CRP does not equal quiescent disease — arterial lesions progress silently in a substantial minority, and tocilizumab artificially normalises these markers. Serial imaging is required.
• Surgical pearl: revascularise during remission, and prefer bypass over angioplasty/stenting for critical stenosis.